Radiotherapy plus temozolomide with or without anlotinib in H3K27M ‐mutant diffuse midline glioma: A retrospective cohort study
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14730 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Chao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Indoles, Quinolines, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nature Science Foundation of Hunan Province, National Natural Science Foundation of China, Nature Science Youth Foundation of Hunan Province.
Abstract (Originalsprache)
Background
Besides the hallmark of H3K27M mutation, aberrant amplifications of receptor tyrosine kinases (RTKs) are commonly observed in diffuse midline glioma (DMG), a highly malignant brain tumor with dismal prognosis. Here, we intended to evaluate the efficacy and safety of a multitarget RTK inhibitor anlotinib in patients with H3K27M‐DMG.
Methods
A total of 40 newly diagnosed H3K27M‐DMG patients including 15 with anlotinib and 25 without anlotinib treatment were retrospectively enrolled in this cohort. Progression‐free survival (PFS), overall survival (OS), and toxicities were assessed and compared.
Results
The median PFS and OS of all patients in this cohort were 8.5 months (95% CI, 6.5–11.3) and 15.5 months (95% CI, 12.6–17.1), respectively. According to the Response Assessment in Neuro‐Oncology (RANO) criteria, the disease control rate in the anlotinib group [93.3%, 95% confidence interval (CI), 70.2–98.8] was significantly higher than those without anlotinib (64%, 95% CI: 40.5–79.8, p = 0.039). The median PFS of patients with and without anlotinib was 11.6 months (95% CI, 7.8–14.3) and 6.4 months (95% CI, 4.3–10.3), respectively. Both the median PFS and OS of DMG patients treated with anlotinib were longer than those without anlotinib in the infratentorial patients (PFS: 10.3 vs. 5.4 months, p = 0.006; OS: 16.6 vs. 8.7 months, p = 0.016). Multivariate analysis also indicated anlotinib (HR: 0.243, 95% CI: 0.066–0.896, p = 0.034) was an independent prognosticator for longer OS in the infratentorial subgroup. In addition, the adverse events of anlotinib administration were tolerable in the whole cohort.
Conclusions
This study first reported that anlotinib combined with Stupp regimen is a safe and feasible regimen for newly diagnosed patients with H3K27M‐DMG. Further, anlotinib showed significant efficacy for H3K27M‐DMG located in the infratentorial region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Chao Liu
Förderung
- Nature Science Foundation of Hunan Province
- National Natural Science Foundation of China
- Nature Science Youth Foundation of Hunan Province
- Natural Science Foundation of Hunan Province
Zitieren
APA
Liu, C., Kuang, S., Huang, T., Wu, J., Zhang, L., & Gong, X. (2024). Radiotherapy plus temozolomide with or without anlotinib in H3K27M ‐mutant diffuse midline glioma: A retrospective cohort study. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14730
Vancouver
Liu C, Kuang S, Huang T, Wu J, Zhang L, Gong X. Radiotherapy plus temozolomide with or without anlotinib in H3K27M ‐mutant diffuse midline glioma: A retrospective cohort study. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14730
BibTeX
@article{Liu2024,
author = {Liu, Chao and Kuang, Shuwen and Huang, Tianxiang and Wu, Jun and Zhang, Longbo and Gong, Xuan},
title = {Radiotherapy plus temozolomide with or without anlotinib in H3K27M ‐mutant diffuse midline glioma: A retrospective cohort study},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14730}
}
EUVIMED